Mastocytosis and insect venom allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 4, 2010, Pages 347-353

  Bonadonna, Patrizia ^a   Zanotti, Roberta ^a   Müller, Ulrich ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b Allergy Division   (Switzerland)

Author keywords

hymenoptera venom allergy; mastocytosis; serum tryptase; venom immunotherapy

Indexed keywords

HYMENOPTERA VENOM; TRYPTASE; VENOM; ANTIALLERGIC AGENT; ARTHROPOD VENOM; WASP VENOM;

ANAPHYLAXIS; DISEASE CLASSIFICATION; IMMUNOTHERAPY; INSECT ALLERGY; INSECT STING; LABORATORY TEST; MAST CELL; MASTOCYTOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD; COMPLICATION; DESENSITIZATION; HUMAN; HYMENOPTERA; HYPERSENSITIVITY, IMMEDIATE; IMMUNOLOGY; INSECT BITE; PROCEDURES;

ANAPHYLAXIS; ANIMALS; ANTI-ALLERGIC AGENTS; ARTHROPOD VENOMS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYMENOPTERA; HYPERSENSITIVITY, IMMEDIATE; INSECT BITES AND STINGS; MASTOCYTOSIS; TRYPTASES; WASP VENOMS;

EID: 77954660356     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833b280c     Document Type: Review

References (49)

1. Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100:11-15.
2. Oude Elberink JNK, de Monchy JGR, Kors JW, et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99:153-161.
3. Dubois AE. Mastocytosis and hymenoptera allergy. Curr Opin Allergy Clin Immunol 2004; 4:291-295.
4. Rueff F, Placzek M, Przybilla B. Mastocytosis and hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006; 6:284-288.
5. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216-1220.
6. Florian S, Krauth MT, Simonitsch-Klupp I, et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005; 136:273-280.
7. Gonzá lez de Olano D, de la Hoz Caballer B, Núñez Ló pez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37:1547-1555.
8. Brockow K, Jofer C, Behrendt H, et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226-232.
9. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680-686.
10. Ludolph-Hauser D, Rueff F, Fries C, et al. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to hymenoptera stings. Lancet 2001; 357:361-362.
11. Rueff F, Przybilla B, Bilò MB, et al. Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group of Insect venom hypersensitivity. J Allergy Clin Immunol 2009; 129:1047-1054.
12. Severino MG, Campi P, Macchia D, et al. European Polistes venom allergy. Allergy 2006; 61:860-863.
13. Bilò MB, Rueff F, Mosbech H, et al. Diagnosis of hymenoptera venom allergy. 2005; 60:1339-1349.
14. Bonifazi F, Jutel M, Biló BM, et al. EAACI Interest Group on insect venom hypersensitivity: prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-1470.
15. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316:1622-1626.
16. Schwartz LB, Yunginger JW, Millr J, et al. Time course of appearance and disappearance of human mast cell tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14:190-204.
17. Piao X, Bernstein A. A point mutation in the catalytic domain of c-Kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996; 87:3117-3123.
18. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603-625.
19. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37:435-453.
20. Rosbotham JL, Malik NM, Syrris P, et al. Carter ND: lack of c-Kit mutation in familial urticaria pigmentosa. Br J Dermatol 1999; 140:849-852.
21. Escribano L, Akin C, Castells M, et al. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006; 5:61-77.
22. Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002; 127:147-152.
23. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast cell population with clonal markers in a subset of patients with 'idiopathic' anaphylaxis. Blood 2007; 110:2331-2333.
24. Sonneck K, Florian S, Mullauer L, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007; 142:158-164.
25. Bonadonna P, Zanotti R, Pagani M, et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy 2009; 64:1379-1382.
26. Müller UR, Horat W, Wuthrich B, et al. Anaphylaxis after hymenoptera sting in three patients with urticaria pigmentosa. J Allergy Clin Immunol 1983; 72:685-689.
27. Kors JW, van Doormaal JJ, de Monchy JG. Anaphylactoid shock following hymenoptera sting as a presenting symptom of systemic mastocytosis. J Intern Med 1993; 233:255-258.
28. Biedermann T, Ruëff F, Sander CA, Przybilla B. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol 1999; 141:1110-1112.
29. Pumphrey RS. Fatal anaphylaxis in the UK, 1992-2001. Novartis Found Symp 2004; 257:116-128.
30. Wein M. Sting anaphylaxis and urticaria pigmentosa. J Allergy Clin Immunol 1998; 101:432.
31. Potier A, Lavigne C, Chappard D, et al. Cutaneous manifestations in hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin Exp Allergy 2009; 39:717-725.
32. Guenova E, Volz T, Eichner M, et al. Basal serum tryptase as risk assessment for severe hymenoptera sting reactions in elderly. Allergy 2010. [Epub ahead of print]
33. Dugas-Breit S, Przybilla B, Dugas M, et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for hymenoptera venom allergy. Clin Exp Allergy 2010; 40:643-649.
34. Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010; 115:150-151.
35. Hofmann DR, Jacobson RS. Allergens in hymenoptera venom XII: how much protein is in a sting? Ann Allergy 1984; 52:276-278.
36. Müller U, Helbling A, Hunziker T, et al. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990; 45:597-603.
37. Müller UR, Haeberli G. The problem of anaphylaxis and mastocytosis. Curr Allergy Asthma Rep 2009; 9:64-70.
38. Gonzá lez de Olano D, Alvarez-Twose I, Esteban-Ló pez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519-526.
39. Metcalfe D, Schwartz L. Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol 2009; 123:687-688.
40. Niedoszytko M, de Monchy J, van Doormaal JJ, et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237-1245.
41. Engler RJ, Davis WS. Rush hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease. J Allergy Clin Immunol 1994; 94:556-559.
42. Bonadonna P, Zanotti R, Caruso B, et al. Allergen specific immunotherapy is safe and effective in patients with mastocytosis and hymenoptera allergy. J Allergy Clin Immunol 2008; 121:256-257.
43. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000; 55:484-488.
44. Wedi B, Wieczorek D, RoapV, Kapp A. Anti-IgE treatemnt overcomes intolerability of honey bee venom ultra-rush immunotherapy in indolent systemic mastocytosis. J World Allergy Org 2007; (Suppl 2):182-183.
45. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immuno-therapy in indolent systemic mastocytosis. Allergy 2008; 55:484-488.
46. Müller UR, Mosbech H, editors. Position paper: immunotherapy with hymenoptera venoms. EAACI Subcommittee on Insect Venom Allergy. Allergy 1993; 48:36-46.
47. Bilò MB, Bonifazi F. Advances in hymenoptera venom immunotherapy. Curr Opin Allergy Clin Immunol 2007; 7:567-573.
48. Reimers A, Müller U. Fatal outcome of a Vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. Swiss Med Wkly 2005; 135:S14.
49. Wagner N, Fritze D, Przybilla B, et al. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Immunol 2008; 146:162-163.